| Valuation method | Value, ¥ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 4495.39 | -17 |
| Intrinsic value (DCF) | 2617.76 | -52 |
| Graham-Dodd Method | 1909.74 | -65 |
| Graham Formula | 505.18 | -91 |
Kobayashi Pharmaceutical Co., Ltd. (4967.T) is a leading Japanese consumer goods company specializing in healthcare, skincare, body warmers, and household products. Founded in 1886 and headquartered in Osaka, the company has built a strong reputation for innovative and high-quality consumer health solutions. Its diverse product portfolio includes well-known brands such as Ammeltz (topical analgesic), Inochi no Haha (women's health medicine), and Bluelet Decoral (toilet cleaner). Kobayashi operates across pharmaceuticals, quasi-drugs, cosmetics, and health foods, leveraging both traditional retail and e-commerce channels. With a market capitalization of approximately ¥377 billion, the company maintains a stable presence in Japan and internationally. Its focus on R&D and consumer-centric product development positions it as a key player in the Household & Personal Products sector, catering to the growing demand for health and wellness solutions in an aging society.
Kobayashi Pharmaceutical presents a stable investment opportunity within the Consumer Defensive sector, supported by its strong brand recognition and diversified product portfolio. The company's low beta (0.469) suggests lower volatility compared to the broader market, making it attractive for risk-averse investors. However, its modest net income (¥10.07 billion) and high capital expenditures (¥-26.06 billion) indicate potential margin pressures. The dividend yield, with a payout of ¥102 per share, adds income appeal. Investors should monitor Japan's demographic trends (aging population) and the company's ability to expand internationally for sustained growth.
Kobayashi Pharmaceutical holds a competitive edge through its deep-rooted brand trust and diversified product range in Japan’s consumer health market. Its strength lies in niche categories like topical analgesics (Ammeltz) and women’s health products (Inochi no Haha), where it faces limited direct competition. However, the company operates in a highly competitive Household & Personal Products industry, contending with global giants like Kao Corp. and local players such as Lion Corp. Kobayashi’s focus on quasi-drugs and healthcare differentiates it from pure-play cosmetics or household product manufacturers. Its e-commerce strategy and direct marketing campaigns enhance customer engagement, but international expansion remains limited compared to peers. The company’s R&D investments in functional health products align with Japan’s aging population trends, but reliance on domestic markets poses concentration risks. Capital expenditures are high, likely for production modernization, which could pressure short-term profitability.